Cyabra receives Nasdaq listing deficiency notice
Cyabra, Inc. has received two deficiency notices from Nasdaq, signaling that its stock no longer meets key continued listing standards.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Cyabra, Inc. has received two deficiency notices from Nasdaq, signaling that its stock no longer meets key continued listing standards. Nasdaq found that Cyabra’s Market Value of Publicly Held Shares was below $15,000,000 for 30 consecutive business days ended June 8, 2026, and its common stock traded below the minimum bid price of $1.00 per share for the same period.
The stock remains listed on Nasdaq under the symbol CYAB while the company has until December 7, 2026 to cure both issues, including achieving the required levels for at least ten consecutive business days. If Cyabra fails to regain compliance, its shares could be delisted, although the company may appeal or seek transfer to Nasdaq’s Capital Market. Cyabra states it is working diligently and monitoring its share price, but it cautions there is no assurance it will regain compliance.
Positive
- None.
Negative
- Nasdaq listing at risk: Cyabra no longer satisfies Nasdaq’s minimum $15,000,000 Market Value of Publicly Held Shares requirement and $1.00 minimum bid price rule, and faces potential delisting if it cannot regain compliance by December 7, 2026.
Insights
Nasdaq deficiency notices put Cyabra’s current Nasdaq listing at risk.
Cyabra has fallen below Nasdaq standards on both market value of publicly held shares and minimum bid price. These are core listing requirements: an MVPHS of at least $15,000,000 and a share price of at least $1.00 for 30 consecutive business days.
The company has a 180-day compliance window until December 7, 2026 to restore both metrics for at least ten consecutive business days. If it fails, Nasdaq can move toward delisting, though Cyabra can appeal or seek transfer to the Capital Market if it meets those standards.
This situation is meaningfully negative because losing a Nasdaq Global Market listing can reduce liquidity and access to capital. The company’s statement that there is “no assurance” of regaining compliance underlines the uncertainty; investors will rely on future disclosures to see whether the metrics recover within the allowed period.
8-K Event Classification
Key Figures
Key Terms
Minimum Bid Rule financial
Nasdaq Listing Rule 5450(b)(2)(C) regulatory
Nasdaq Listing Rule 5450(a)(1) regulatory
Nasdaq Hearings Panel regulatory
Capital Market financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What Nasdaq listing rules did Cyabra (CYAB) fail to meet?
Is Cyabra (CYAB) being delisted from Nasdaq right now?
How can Cyabra (CYAB) regain compliance with Nasdaq’s MVPHS rule?
What must Cyabra (CYAB) do to fix the minimum bid price deficiency?
What happens if Cyabra (CYAB) does not regain Nasdaq compliance by December 7, 2026?
Can Cyabra (CYAB) receive additional time to meet Nasdaq’s minimum bid requirement?
AI-generated analysis. How Rhea-AI works. Not financial advice.